摘要
目的：评价美洛西林钠/舒巴坦钠治疗急性细菌性感染疾病的安全性、有效性及药物不良反应。方法：本研究采用多中心随机对照的方法，比较研究了国产美洛西林钠/舒巴坦钠每次3.75g、每12h或8h 1次，与替卡西林/克拉维酸每次3.2g、每12h或8h1次应用治疗急性细菌性感染的临床疗效和安全性。结果：试验组的痊愈率和有效率分别为76.36%和99.09%，细菌清除率为92.78%；对照组的痊愈率和有效率分别为62.24%和88.78%，细菌清除率为91.95%，两组差异无统计学意义。试验中未发现应用美洛西林钠/舒巴坦钠的严重药物不良反应。结论：国产美洛西林钠/舒巴坦钠对急性细菌性感染的临床疗效较好而不良反应较少。
OBJECTIVE: To evaluate the clinical efficacy and safty and adverse drug reaction of mezlocillin/sulbactam for acute bacterial infections. METHODS: A randomized controlled multicentre clinical trial on efficacy and safety of domestic mezlocillin/sulbactam in 3.75g every 8 hours(or 12 hours) compared with timentin in 3.2g every 8 hours(or 12 hours) for treatment of acute bacterial infections was conducted. RESULTS: The results showed that the the cure rates and efficacy rates in the test group were 76.36% and 99.09%, the bacterial clearance rate was 92.78%, while the cure rates and efficacy rates in the control group were 62.24% and 88.78%, and the bacterial clearance rate was 91.95%, the differerence between the two groups was no statistically significant. There were no serious adverse drug reactions of mezlocillin/sulbactam in the clinical trial. CONCLUSION: It suggested that mezlocillin/sulbactam is an effective and safe drug for treatment acute bacterial infections.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2000年第5期327-331,共5页
The Chinese Journal of Clinical Pharmacology
